17 MAY, 2023

Preliminary data presented at DDW suggests Atmo Gas Capsule could be used as diagnostic tool for SIBO

Preliminary results from a University of Queensland (UQ) study to assess how the Atmo Gas Capsule compares to established SIBO (small intestinal bacterial overgrowth) diagnostic methods suggest a good correlation with duodenal aspirate and higher accuracy than a breath test.

Dr Ayesha Shah, a senior lecturer at the UQ School of Medicine, presented data from the study, led by Professor Gerald Holtmann, also from UQ, and Professor Uday Chand Ghoshal of Sanjay Gandhi Postgraduate Institute of Medical Sciences, India, in a presentation at Digestive Disease Week (DDW), held May 6-9 in Chicago.

READ MORE

15 MAY, 2023

Results presented at DDW show Atmo Gas Capsule can be used to assess whole gut transit time in patients with dysmotility

A Western Sydney University (WSU) and Monash University comparative study has validated the Atmo Gas Capsule relative to the SmartPill when measuring gastric emptying time and colonic transit time in patients with gastroparesis and chronic constipation. Dr Jerry Zhou, lecturer and clinical researcher at WSU School of Medicine, presented findings from the study in a poster presentation at Digestive Disease Week  (DDW), held May 6-9 in Chicago.

READ MORE

1 MAY, 2023

Atmo Biosciences appoints world-renowned gastroenterologist Professor Eamonn Quigley as Medical Advisory Board Chair

Prof. Quigley is David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology at Houston Methodist Hospital in Texas. He is internationally known for his research on gastrointestinal motility disorders, particularly irritable bowel syndrome (IBS) and its link to the gut microbiome. As Atmo MAB Chair, Prof. Quigley will provide leadership and guidance regarding Atmo’s clinical trials portfolio.

READ MORE

17 APRIL 2023

Atmo Biosciences strengthens U.S. focus with new board appointment and establishment of San Diego office

Atmo Biosciences is strengthening its U.S. focus with the appointment of experienced medical device executive Chris Bertrand to the Atmo Board and establishment of a San Diego, California office.
The increased presence in the U.S. comes as Atmo Biosciences prepares to begin a multi-site pivotal study to support a U.S. Food and Drug Administration (FDA) submission around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility.

30 MARCH 2023

Atmo Biosciences closes fully subscribed $8 million Series B funding round

Atmo Biosciences has raised A$8 million in a fully subscribed Series B funding round.
The raise was led by Japanese multinational company Otsuka Pharmaceutical, an existing strategic shareholder that took up more than its pro rata entitlement.

2 NOVEMBER 2022

Atmo Biosciences and RMIT University Granted European and Australian Patents for Ingestible Gas-Sensing Capsule.

Atmo Biosciences is pleased to announce that the European Patent Office and IP Australia have each granted patents related to key intellectual property for Atmo’s ingestible gas sensor capsule, providing coverage until 2037. This follows the recent granting of the equivalent patent in the USA which was announced in September 2022.

2 NOVEMBER 2022

Atmo Biosciences Successfully Completes ISO 13485:2016 Audit

Atmo Biosciences is pleased to announce that it has successfully completed the audit of its Quality Management System to obtain ISO 13485:2016 accreditation.

4 OCTOBER 2022

Positive Atmo Capsule Clinical Trial results published

Atmo Biosciences is pleased to announce publication of a clinical study demonstrating strong agreement between data from Atmo’s world-first ingestible gas-sensing capsule and and a validated, FDA-cleared Wireless Motility Capsule (WMC), in determining transit metrics in healthy subjects.

15 SEPTEMBER 2022

Atmo Biosciences and RMIT University granted US patent for Ingestible Gas Sensor Capsule.

Atmo Biosciences is pleased to announce that the US Patent and Trademark Office (USPTO) has granted the patent for Atmo’s ingestible gas sensor capsule.

26 JULY 2022

Atmo Biosciences Appoints Medical Advisory Board

Atmo Biosciences has appointed a Medical Advisory Board (MAB), comprising world-renowned gastroenterologists. The Atmo MAB consists of six gastroenterologists selected for their specialist expertise and interest in functional gut disorders and related conditions, many of which Atmo is targeting. The MAB members are highly regarded key opinion leaders in their respective fields and have extensive experience with wireless motility capsule technology.

26 JULY 2022

Atmo Biosciences strengthens executive leadership team and Board of Directors

Atmo Biosciences Limited, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gut health and microbiome function, has made three key appointments, further building capability at the executive and Board levels.